Board summary
Key figures
31,459
Registered population
52.7% aged 18–64
31.8%
Aged 65+
ICB 21.9% · England 17.9%
6.5%
Ethnic minority (non-White)
2.8% Asian · England 9.6%
0.8%
In IMD quintile 1
ICB 9.2% · England 21.0%
~252
Core20 residents (est.)
Resident basis; registered basis ~260 · see page 3
6,405
Hypertension register
+4.52% in 3 yrs · England +5.60%
308
SMI register
15.4% of Arun's
682
COPD register
Reviews +6.61% in 3 yrs
Forecast to 2030
7,242
Hypertension patients, 2030
+837 on today
60.1%
QRISK ≥20% on statins, 2030
+1.11pp over 3 yrs
4.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension control and recent recording trail England.
Hypertension control is 57.9% (England 70.3%, -3.2% over 2023 to 2025) and BP recording is 82.7% (England 90.0%), which may reflect review capacity.
Smoking cessation offers and asthma recording lag.
Smoking cessation offers are 81.5% (England 94.2%, -3.6 pp over 2023 to 2025) and youth asthma second-hand smoke recording is 65.5% (England 78.8%).
SMI physical checks and breast screening lead.
SMI blood pressure checks reach 87.8% (England 83.4%, +12.5 pp over 2023 to 2025), alongside 85.7% BMI recording and 82.3% breast screening (England 69.9%).
Population, age and ethnicity
Patients aged 65 and over comprise 31.8% of the list, well above England
Across 31,459 registered patients, 31.8% (9,990) are aged 65+, compared to 29.2% in Arun, 21.9% in NHS Sussex Integrated Care Board, and 17.9% in England. Between practices, this ranges from 28.8% at Lime Tree Surgery to 52.8% at Barn Surgery. Census estimates for resident catchments show 93.5% White (Arun 95.8%, NHS Sussex Integrated Care Board 91.0%, England 81.1%) and a 6.5% ethnic minority share, including 2.8% Asian / Asian British residents (Arun 1.6%, NHS Sussex Integrated Care Board 3.7%, England 9.6%). These census figures describe local residents rather than registered patients.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Arun local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Arun LA) | 2,327 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.9% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Arun LA) | 1,216 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Arun LA) | 13.3 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is low overall with all estimated 260 Core20 patients at Lime Tree Surgery
Average IMD decile is 7.4, compared with 5.6 in Arun, 6.1 in NHS Sussex Integrated Care Board, and 5.5 in England. Registered patients in Core20 areas stand at 0.8%, below Arun (9.8%), NHS Sussex Integrated Care Board (9.2%), and England (21.0%). Core20 volume is concentrated at Lime Tree Surgery with an estimated 260 patients (0.9% share), while Barn Surgery records 0.0%. Modelled practice figures differ from the 252 estimated Core20 residents. Core20 interventions require focused practice targeting rather than PCN-wide deployment.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
308
SMI register
0.97% recorded prevalence
229
Learning disability register
0.72% recorded prevalence
27
Care homes, 695 beds
In the PCN catchment
8.9%
Provide unpaid care
Arun, Census 2021
Recorded registers include 308 patients on the severe mental illness register (1.0%, matching England 1.0%) and 229 with learning disabilities (0.7% vs England 0.6%). Catchment infrastructure includes 27 care homes with 695 beds, though this does not confirm registered resident numbers. With learning disability prevalence above England, annual health checks and care-home multidisciplinary reviews are the key inclusion workloads to sustain.
Severe mental illness: physical health checks
SMI checks exceed England for blood pressure (87.8% vs 83.4%) and BMI (85.7% vs 82.1%). Smoking cessation offers trail at 81.5% (England 94.2%), falling 3.6 pp over 2023 to 2025 (England +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,405
Hypertension register
+4.52%
Register growth, 3 yrs
Arun +4.55% · England +5.60%
+0.27pp
BP control, under 80
≤140/90 · +2.06pp aged 80+
+837
More patients by 2030
Forecast 7,242 (22.08%)
Hypertension case-finding and control
The PCN records hypertension prevalence of 20.2% (6,405 patients), above Arun (19.8%), NHS Sussex Integrated Care Board (16.3%) and England (15.2%). Blood pressure recording trails at 82.7% against Arun (89.4%), NHS Sussex Integrated Care Board (90.2%) and England (90.0%), falling 2.8% over 2023 to 2025 (England +3.6%). Patients treated to target reached 57.9% against Arun (68.8%), NHS Sussex Integrated Care Board (69.1%) and England (70.3%), falling 3.2% (England +3.6%). Recording is 84.8% at Lime Tree Surgery and 73.2% at Barn Surgery; control is 60.1% at Lime Tree Surgery and 48.6% at Barn Surgery. Hypertension monitoring and control trail England, so prioritizing structured recall and medication titration could improve control.
Lipids and statins
Among patients with QRISK ≥ 20%, lipid-lowering therapy reaches 57.8%, trailing Arun (62.5%), NHS Sussex Integrated Care Board (60.0%) and England (63.6%), with growth of +1.9% over 2023 to 2025 behind England (+6.2%). Lower uptake than comparators suggests scope to review clinical recall for at-risk patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 74,729 | £2.70 | £2.42 | £1.86 | £201,768 |
| Cardiovascular (all), 2025 | 98,778 | £3.03 | £3.32 | £3.33 | £299,297 |
For lipid-regulating drugs in 2026, the PCN prescribed 74,729 items at £2.70 per item, below Arun (£2.81) but above NHS Sussex Integrated Care Board (£2.42) and England (£1.86), spending £62,772 more than at England's unit cost across 74,729 items. This unit-cost indicator does not establish inefficiency, though formulary review could explore cost drivers.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+13.09%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.53%
Asthma prevalence, PCN 3-yr % change
The PCN records 682 COPD patients (2.1% prevalence vs England 1.9%) and 2,279 asthma patients (7.5% vs England 6.6%). COPD 12-month reviews reach 69.3% (England 76.4%), with Lime Tree Surgery at 67.2% and Barn Surgery at 82.3%. Second-hand smoke status recording for asthma patients aged 6 to 19 is 65.5% (England 78.8%), while asthma management items prescribed per 1,000 population aged 5 to 19 is 1,933 (England 1,488). Review shortfalls and pediatric exposure recording gaps suggest scope for proactive respiratory follow-up.
Cancer register and children's immunisation
The cancer register records 1,440 patients (4.5% prevalence vs England 3.8%), with three-year growth of +2.6% over 2023 to 2025 behind England (+9.0%). In Q1 2025/26, MMR dose 1 at age five reached 98.2% (target 95.0%), but dose 2 was 91.1% (denominator 60), trailing dose 1 by 7.1 pp and falling below the 95.0% target by 3.9 pp. The cross-sectional dose gap highlights potential for targeted pre-school recall.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In NHS Sussex ICB, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2 in 2022, above England (55.3%) but 16.5 percentage points below the 75.0% ambition by 2028. Staging completeness was 64.3% (8,209 of 12,766). Reaching the ICB ambition requires about 1,360 extra early-stage diagnoses yearly. Locally, breast (82.3%) and cervical screening (70.8%) exceed England (69.9% and 66.8%), yet PCN cancer register growth was +2.6% over 2023 to 2025 (England +9.0%), spanning +0.3% at Lime Tree Surgery to +12.4% at Barn Surgery. Slower register expansion may indicate under-recording of diagnosed cases, warranting systematic reconciliation.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day standard (414 of 635), trailing Royal Surrey NHS Foundation Trust (84.5%), Surrey and Sussex Healthcare NHS Trust (70.0%), NHS Surrey and Sussex Integrated Care Board (71.5%), England (71.2%), and the 85.0% standard. Its 28-day faster diagnosis performance was 74.0%, below England (79.3%) and the 75.0% standard. Across all diagnostic tests, 12.9% waited 6+ weeks, but colonoscopy reached 39.3% (England 30.8%). Acute pathway and endoscopy bottlenecks could delay diagnosis and treatment following primary care referral.
| Pathways within standard (%) | Sussex | Surrey and Sussex Healthcare | Royal Surrey | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 77.74 | 82.62 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 96.20 | 96.43 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 69.97 | 84.48 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | Surrey and Sussex Healthcare | Royal Surrey | England |
|---|---|---|---|---|
| MRI | 5.62 | 27.53 | 0.00 | 21.40 |
| CT | 8.57 | 18.49 | 0.15 | 9.92 |
| Echocardiography | 0.39 | 43.78 | 1.55 | 28.48 |
| Colonoscopy | 39.35 | 15.11 | 0.00 | 30.83 |
| Gastroscopy | 20.02 | 21.06 | 0.00 | 29.02 |
| All 15 DM01 tests | 12.95 | 28.50 | 8.82 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026, provisional community services recorded 78,050 care contacts across 19,770 West Sussex residents, with 115,485 care activities and 16,015 referrals. Adults aged 65+ accounted for 72.7% of these contacts (56,740). Across NHS Surrey and Sussex Integrated Care Board, 85,660 patients had 309,615 community contacts. Heavy community utilisation among older residents underlines the need for joined-up post-diagnosis cancer and palliative support.
Practice variation and patient experience
Phone contact ease varies widely between practices despite similar overall satisfaction
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Barn Surgery | 129 | 0.0 | 78.1% | 70.1% | 75.2% |
| Lime Tree Surgery | 104 | 0.9 | 54.0% | 77.8% | 73.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nine three-year clinical trajectories lag England, led by declining hypertension control
Across 25 tracked trajectories (2023 to 2025), 9 measures lag England. Hypertension control fell 3.2% (England +3.6%, Arun +3.2%), blood pressure recording fell 2.8% (England +3.6%), and smoking cessation offers dropped 3.6 pp (England +0.1 pp) to 81.5% (England 94.2%). QRISK ≥ 20% statin therapy grew 1.9% (England +6.2%). Conversely, severe mental illness checks surged, led by BMI recording up 19.3 pp (England +5.1 pp) and alcohol recording up 18.2 pp (England +5.4 pp). Heart failure reviews rose 125.3% (England +8.7%), although PCN review coverage remains 71.7% against 78.5% in England.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Hypertension treated to target
Cancer register
Hypertension BP reading
QRISK statin treatment
Smoking support (SMI)
Heart failure reviews
BMI record (SMI)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Arun | Asset | PCN | Arun |
|---|---|---|---|---|---|
| Care homes (catchment) | 27 (695 beds) | n/a | Schools (catchment) | 28 | n/a |
| Children's centres | 4 | 7 | Places of worship | 26 | 68 |
| Libraries | 4 | 7 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 10 | 21 | Primary academies | 5 | 19 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured hypertension recall and titration
Across 6,405 hypertensive patients (20.2% prevalence), control is 57.9% (12.4 pp below England's 70.3%, falling 3.2% vs England +3.6%) and recording is 82.7% (England 90.0%). For discussion: establish pharmacist-led recall and titration for uncontrolled hypertensive patients at Barn Surgery (48.6% control) and Lime Tree Surgery (60.1%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Smoking cessation offer template review
Smoking cessation support offered is 81.5% (denominator includes PCAs), 12.7 pp below England (94.2%) and 13.2 pp below Arun (94.7%), falling 3.6 pp (England +0.1 pp). For discussion: standardise review templates and prompts across both practices so smoking cessation offers and pediatric second-hand smoke checks are consistently recorded. Low cost, quick to run.
Option 3
High-risk lipid therapy and formulary review
QRISK ≥ 20% lipid therapy is 57.8% (5.8 pp below England's 63.6%, growing +1.9% vs England +6.2%); 2026 lipid-modifying prescribing spent £62,772 more than at England's unit cost across 74,729 items. Moderate effort to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive frailty review planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation protocol review (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration (p5) | Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register coding reconciliation (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured hypertension recall and titration (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Smoking cessation offer template review (p12) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | — | PCN |
| Option 3 · High-risk lipid therapy and formulary review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Count of Items prescribed for Lipid-regulating drugs 2026 | — | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
